Contribution: Industrial Research Assistance Program
Providence Therapeutics Holdings Inc.
$2,128,801.00
H5N1 -mRNA vaccine for Highly Pathogenic Avian Influenza for Protection of Canadian Livestock
FY 2024-25 · 2024-06-01
Summary
This proposal aims to develop a made-in-Canada solution to the threat posed by Highly Pathogenic Avian Influenza (HPAI) to Canadian livestock. Providence Therapeutics will initiate work to design and develop an mRNA vaccine drug candidate for a relevant strain using their mRNA and INTENT lipid nanoparticle (LNP) platforms.
Department
Program
Industrial Research Assistance Program
Location
Calgary|Calgary, Alberta, Canada
Recipient Type
For-profit organization
Business Number
738045079
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2024-06-01 | 2024-25 | $1,783,815.00 |
| 1 | 2024-06-01 | 2024-25 | $2,128,801.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 119 days. The total amended value is 344,986 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 119 jours. La valeur totale des modifications est de 344 986 dollars.
Agreement End Date
2026-07-01
Agreement Number
1028947
Agreement Start Date
2024-06-01
Agreement Title
H5N1 -mRNA vaccine for Highly Pathogenic Avian Influenza for Protection of Canadian Livestock
Agreement Title (French)
Vaccin à ARNm H5N1 contre la grippe aviaire hautement pathogène pour la protection du bétail canadien
Agreement Type
Contribution
Agreement Value
$2,128,801.00
Amendment Date
2026-03-31
Amendment Number
1
Coverage
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity. | Les projets du Programme d'aide à la recherche industrielle favorisent la création de richesse au Canada grâce à l'innovation technologique et renforcent l'écosystème canadien de l'innovation en créant de nouvelles capacités industrielles.
Description
This proposal aims to develop a made-in-Canada solution to the threat posed by Highly Pathogenic Avian Influenza (HPAI) to Canadian livestock. Providence Therapeutics will initiate work to design and develop an mRNA vaccine drug candidate for a relevant strain using their mRNA and INTENT lipid nanoparticle (LNP) platforms.
Description (French)
Cette proposition vise à développer une solution canadienne à la menace que représente la grippe aviaire hautement pathogène (GAHP) pour le bétail canadien. Providence Therapeutics va commencer à concevoir et à développer un vaccin expérimental à ARNm pour une souche pertinente en utilisant ses plateformes d’ARNm et de nanoparticules lipidiques (NPL) INTENT.
Expected Results
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Expected Results (French)
Les résultats attendus du Programme d’aide à la recherche industrielle du CNRC sont axés sur la croissance des petites et moyennes entreprises (PME) grâce à l’innovation et à la création de richesse pour le Canada.
Federal Riding
Calgary Midnapore
Federal Riding (French)
Calgary Midnapore
Federal Riding Number
48008
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program
Program Name (French)
Programme d’aide à la recherche industrielle
Program Purpose
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Program Purpose (French)
Les contributions versées aux entreprises en vertu du Programme d’aide à la recherche industrielle ont pour objectif d’apporter un soutien aux petites et moyennes entreprises (PME) afin qu’elles puissent approfondir leurs connaissances en matière d’innovation et renforcer leur capacité d’innovation, de croissance et de création de richesse pour le Canada.
Recipient Business Number
738045079
Recipient City
Calgary|Calgary
Recipient Country
CA
Recipient Legal Name
Providence Therapeutics Holdings Inc.
Recipient Postal Code
T2J 3J1
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2024-2025-Q4-1028947
